You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

~ Buy the SYMTUZA (cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate) Drug Profile, 2024 PDF Report in the Report Store ~

SYMTUZA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Symtuza, and what generic alternatives are available?

Symtuza is a drug marketed by Janssen Prods and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has four hundred and eighty-five patent family members in fifty-one countries.

The generic ingredient in SYMTUZA is cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate profile page.

DrugPatentWatch® Generic Entry Outlook for Symtuza

Symtuza was eligible for patent challenges on November 5, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 6, 2032. This may change due to patent challenges or generic licensing.

There have been thirty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for SYMTUZA?
  • What are the global sales for SYMTUZA?
  • What is Average Wholesale Price for SYMTUZA?
Summary for SYMTUZA
Drug patent expirations by year for SYMTUZA
Drug Prices for SYMTUZA

See drug prices for SYMTUZA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SYMTUZA
Generic Entry Date for SYMTUZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SYMTUZA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
East Carolina UniversityPhase 4
Chelsea and Westminster NHS Foundation TrustPhase 3
Imperial College LondonPhase 3

See all SYMTUZA clinical trials

Paragraph IV (Patent) Challenges for SYMTUZA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SYMTUZA Tablets cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate 800 mg/150 mg/ 200 mg/10 mg 210455 1 2021-08-16

US Patents and Regulatory Information for SYMTUZA

SYMTUZA is protected by fifteen US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of SYMTUZA is ⤷  Subscribe.

This potential generic entry date is based on patent 10,039,718.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Prods SYMTUZA cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210455-001 Jul 17, 2018 RX Yes Yes 8,754,065 ⤷  Subscribe Y Y ⤷  Subscribe
Janssen Prods SYMTUZA cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210455-001 Jul 17, 2018 RX Yes Yes 10,786,518 ⤷  Subscribe ⤷  Subscribe
Janssen Prods SYMTUZA cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210455-001 Jul 17, 2018 RX Yes Yes 7,390,791 ⤷  Subscribe Y Y ⤷  Subscribe
Janssen Prods SYMTUZA cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210455-001 Jul 17, 2018 RX Yes Yes 10,039,718 ⤷  Subscribe Y ⤷  Subscribe
Janssen Prods SYMTUZA cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210455-001 Jul 17, 2018 RX Yes Yes 9,296,769 ⤷  Subscribe Y Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SYMTUZA

International Patents for SYMTUZA

When does loss-of-exclusivity occur for SYMTUZA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Patent: 89
Patent: The use of solid carrier particles to improve the processability of a pharmaceutical agent
Estimated Expiration: ⤷  Subscribe

Patent: 50
Patent: Tablets for combination therapy
Estimated Expiration: ⤷  Subscribe

Argentina

Patent: 5369
Patent: COMPRIMIDOS PARA TERAPIA DE COMBINACION PARA EL TRATAMIENTO DE INFECCIONES VIRALES.
Estimated Expiration: ⤷  Subscribe

Australia

Patent: 09242451
Patent: The use of solid carrier particles to improve the processability of a pharmaceutical agent
Estimated Expiration: ⤷  Subscribe

Patent: 10210598
Patent: Tablets for combination therapy
Estimated Expiration: ⤷  Subscribe

Patent: 14221210
Estimated Expiration: ⤷  Subscribe

Patent: 15200637
Patent: TABLETS FOR COMBINATION THERAPY
Estimated Expiration: ⤷  Subscribe

Patent: 16250470
Patent: THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT
Estimated Expiration: ⤷  Subscribe

Patent: 17201473
Patent: Tablets for combination therapy
Estimated Expiration: ⤷  Subscribe

Patent: 18267573
Patent: Tablets for combination therapy
Estimated Expiration: ⤷  Subscribe

Brazil

Patent: 0911871
Patent: uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico
Estimated Expiration: ⤷  Subscribe

Patent: 1008664
Patent: comprimidos para a terapia de combinação
Estimated Expiration: ⤷  Subscribe

Canada

Patent: 20856
Patent: UTILISATION DE PARTICULES SUPPORTS SOLIDES POUR AMELIORER L'APTITUDE AU TRAITEMENT D'UN AGENT PHARMACEUTIQUE (THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT)
Estimated Expiration: ⤷  Subscribe

Patent: 50521
Patent: PASTILLES DESTINEES A UNE THERAPIE COMBINEE (TABLETS FOR COMBINATION THERAPY)
Estimated Expiration: ⤷  Subscribe

Chile

Patent: 11001885
Patent: Tableta bicapa oral en donde la primera capa comprende al compuesto de formula i (elvitegravir) y al compuesto de formula ii, y la segunda capa comprende al compuesto de formula iii (emtricitabina) y a la sal de formula iv (sal de tenofovir); metodo para la preparacion, util en el tratar infecciones por vih.
Estimated Expiration: ⤷  Subscribe

China

Patent: 2123700
Patent: The use of solid carrier particles to improve the processability of a pharmaceutical agent
Estimated Expiration: ⤷  Subscribe

Patent: 2307573
Patent: Tablets for combination therapy
Estimated Expiration: ⤷  Subscribe

Patent: 3479584
Patent: Use of solid carrier particles to improve the processability of pharmaceutical agent
Estimated Expiration: ⤷  Subscribe

Patent: 4940937
Patent: The use of solid carrier particles to improve the processability of a pharmaceutical agent
Estimated Expiration: ⤷  Subscribe

Colombia

Patent: 21225
Patent: PARTICULAS PORTADORAS SÓLIDAS PARA MEJORAR LA PROCESABILIDAD DE UN AGENTE FARMACÉUTICO
Estimated Expiration: ⤷  Subscribe

Patent: 00187
Patent: TABLETAS PARA TERAPIA DE COMBINACIÓN
Estimated Expiration: ⤷  Subscribe

Croatia

Patent: 0151009
Estimated Expiration: ⤷  Subscribe

Patent: 0151357
Estimated Expiration: ⤷  Subscribe

Cyprus

Patent: 16852
Estimated Expiration: ⤷  Subscribe

Patent: 17067
Estimated Expiration: ⤷  Subscribe

Denmark

Patent: 96633
Estimated Expiration: ⤷  Subscribe

Patent: 93485
Estimated Expiration: ⤷  Subscribe

Ecuador

Patent: 10010636
Patent: EL USO DE PARTÍCULAS TRANSPORTADORAS SÓLIDAS PARA MEJORAR LA PROCESABILIDAD DE UN AGENTE FARMACÉUTICO
Estimated Expiration: ⤷  Subscribe

Patent: 11011307
Patent: COMPRIMIDOS PARA TERAPIA DE COMBINACION
Estimated Expiration: ⤷  Subscribe

Eurasian Patent Organization

Patent: 1313
Patent: ТАБЛЕТКИ ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ (TABLETS FOR COMBINATION THERAPY)
Estimated Expiration: ⤷  Subscribe

Patent: 2950
Patent: ПРИМЕНЕНИЕ ЧАСТИЦ НОСИТЕЛЯ ДИОКСИДА КРЕМНИЯ ДЛЯ УЛУЧШЕНИЯ ТЕХНОЛОГИЧЕСКИХ ХАРАКТЕРИСТИК ФАРМАЦЕВТИЧЕСКОГО АГЕНТА (USE OF SILICON DIOXIDE CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT)
Estimated Expiration: ⤷  Subscribe

Patent: 0123
Patent: ТАБЛЕТКА ДЛЯ ЛЕЧЕНИЯ ВИЧ И СПОСОБ ЛЕЧЕНИЯ ВИЧ С ЕЕ ПРИМЕНЕНИЕМ (TABLET FOR TREATING HIV AND METHOD OF TREATING HIV USING SAME)
Estimated Expiration: ⤷  Subscribe

Patent: 1071173
Patent: ПРИМЕНЕНИЕ ЧАСТИЦ ТВЁРДОГО НОСИТЕЛЯ ДЛЯ УЛУЧШЕНИЯ ТЕХНОЛОГИЧЕСКИХ ХАРАКТЕРИСТИК ФАРМАЦЕВТИЧЕСКОГО АГЕНТА
Estimated Expiration: ⤷  Subscribe

Patent: 1190125
Patent: ТАБЛЕТКИ ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ
Estimated Expiration: ⤷  Subscribe

Patent: 1491658
Patent: ТАБЛЕТКИ ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ
Estimated Expiration: ⤷  Subscribe

Patent: 1591353
Patent: ПРИМЕНЕНИЕ ЧАСТИЦ ТВЕРДОГО НОСИТЕЛЯ ДЛЯ УЛУЧШЕНИЯ ТЕХНОЛОГИЧЕСКИХ ХАРАКТЕРИСТИК ФАРМАЦЕВТИЧЕСКОГО АГЕНТА
Estimated Expiration: ⤷  Subscribe

European Patent Office

Patent: 96633
Patent: UTILISATION DE VEHICULES PARTICULAIRES SOLIDES POUR FACILITER LA FORMULATION D'UN AGENT PHARMACEUTIQUE. (THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT)
Estimated Expiration: ⤷  Subscribe

Patent: 93485
Patent: COMPRIMÉ BICOUCHE CONTENANT DE L'ELVITEGRAVIR, DU COBICISTAT, DE L'EMTRICITABINE ET DU TENOFOVIR (BILAYER TABLETS COMPRISING ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR)
Estimated Expiration: ⤷  Subscribe

Patent: 06032
Patent: UTILISATION DE PARTICULES SUPPORTS SOLIDES POUR AMÉLIORER L'APTITUDE AU TRAITEMENT D'UN AGENT PHARMACEUTIQUE (THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT)
Estimated Expiration: ⤷  Subscribe

Hong Kong

Patent: 53670
Patent: 利用固體載體顆粒來改進藥劑加工性 (THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT)
Estimated Expiration: ⤷  Subscribe

Patent: 64737
Patent: 包括埃替拉韋, ,恩曲他濱和替諾福韋的雙層片劑 (BILAYER TABLETS COMPRISING ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR COBICISTAT)
Estimated Expiration: ⤷  Subscribe

Patent: 15679
Patent: 固體載體顆粒在改善藥物製劑加工性中的應用 (THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT)
Estimated Expiration: ⤷  Subscribe

Hungary

Patent: 25822
Estimated Expiration: ⤷  Subscribe

Patent: 26380
Estimated Expiration: ⤷  Subscribe

Israel

Patent: 8614
Patent: שימוש בחלקיקי נשא מוצק לשיפור היכולת לעיבוד חומר רוקחי (Use of solid carrier particles to improve the processability of a pharmaceutical agent)
Estimated Expiration: ⤷  Subscribe

Patent: 4227
Patent: טבליות עבור טיפול משולב (Tablets for combination therapy)
Estimated Expiration: ⤷  Subscribe

Japan

Patent: 11242
Estimated Expiration: ⤷  Subscribe

Patent: 22213
Estimated Expiration: ⤷  Subscribe

Patent: 11927
Estimated Expiration: ⤷  Subscribe

Patent: 25171
Estimated Expiration: ⤷  Subscribe

Patent: 11522790
Estimated Expiration: ⤷  Subscribe

Patent: 12517432
Estimated Expiration: ⤷  Subscribe

Patent: 14012741
Patent: USE OF SOLID CARRIER PARTICLE TO IMPROVE PROCESSABILITY OF PHARMACEUTICAL AGENT
Estimated Expiration: ⤷  Subscribe

Patent: 14221845
Patent: 併用治療のための錠剤 (TABLETS FOR COMBINATION THERAPY)
Estimated Expiration: ⤷  Subscribe

Mexico

Patent: 2377
Patent: USO DE PARTICULAS TRASPORTADORAS SOLIDAS PARA MEJORAR LA CAPACIDAD DE PROCESAMIENTO DE UN AGENTE FARMACEUTICO. (THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT.)
Estimated Expiration: ⤷  Subscribe

Patent: 10011963
Patent: USO DE PARTICULAS TRASPORTADORAS SOLIDAS PARA MEJORAR LA CAPACIDAD DE PROCESAMIENTO DE UN AGENTE FARMACEUTICO. (THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT.)
Estimated Expiration: ⤷  Subscribe

Patent: 11008289
Patent: TABLETAS PARA TERAPIA COMBINADA. (TABLETS FOR COMBINATION THERAPY.)
Estimated Expiration: ⤷  Subscribe

New Zealand

Patent: 8978
Patent: THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT
Estimated Expiration: ⤷  Subscribe

Patent: 4214
Patent: TABLETS COMPRISING COBICISTAT, ELVITEGRAVIR, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE FOR COMBINATION THERAPY
Estimated Expiration: ⤷  Subscribe

Peru

Patent: 110994
Patent: COMPRIMIDOS ANTIVIRALES QUE COMPRENDEN ELVITEGRAVIR, EMTRICITABINA, DISOPROXIL FUMARATO DE TENOFOVIR Y UN DERIVADO DE TIAZOL
Estimated Expiration: ⤷  Subscribe

Poland

Patent: 96633
Estimated Expiration: ⤷  Subscribe

Patent: 93485
Estimated Expiration: ⤷  Subscribe

Portugal

Patent: 96633
Estimated Expiration: ⤷  Subscribe

Patent: 93485
Estimated Expiration: ⤷  Subscribe

San Marino

Patent: 01500266
Patent: COMPRESSE A DOPPIO STRATO COMPRENDENTI ELVITEGRAVIR, COBICISTAT, EMTRICITABINA E TENOFOVIR
Estimated Expiration: ⤷  Subscribe

Singapore

Patent: 3544
Patent: TABLETS FOR COMBINATION THERAPY
Estimated Expiration: ⤷  Subscribe

Patent: 0618
Patent: THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT
Estimated Expiration: ⤷  Subscribe

Patent: 14007744
Patent: TABLETS FOR COMBINATION THERAPY
Estimated Expiration: ⤷  Subscribe

Patent: 201609006W
Patent: THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT
Estimated Expiration: ⤷  Subscribe

Patent: 201706215U
Patent: Tablets for combination therapy
Estimated Expiration: ⤷  Subscribe

Slovenia

Patent: 96633
Estimated Expiration: ⤷  Subscribe

Patent: 93485
Estimated Expiration: ⤷  Subscribe

South Africa

Patent: 1008007
Patent: THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT
Estimated Expiration: ⤷  Subscribe

South Korea

Patent: 1645759
Estimated Expiration: ⤷  Subscribe

Patent: 1659971
Estimated Expiration: ⤷  Subscribe

Patent: 1738325
Estimated Expiration: ⤷  Subscribe

Patent: 1784647
Estimated Expiration: ⤷  Subscribe

Patent: 110015581
Patent: THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT
Estimated Expiration: ⤷  Subscribe

Patent: 110122729
Patent: TABLETS FOR COMBINATION THERAPY
Estimated Expiration: ⤷  Subscribe

Patent: 160093100
Patent: 조합 요법용 정제 (TABLETS FOR COMBINATION THERAPY)
Estimated Expiration: ⤷  Subscribe

Patent: 160114728
Patent: 제약 제제의 가공성 향상을 위한 고체 담체 입자의 용도 (THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT)
Estimated Expiration: ⤷  Subscribe

Spain

Patent: 48886
Estimated Expiration: ⤷  Subscribe

Patent: 53897
Estimated Expiration: ⤷  Subscribe

Taiwan

Patent: 44367
Estimated Expiration: ⤷  Subscribe

Patent: 1040142
Patent: Tablets for combination therapy
Estimated Expiration: ⤷  Subscribe

Ukraine

Patent: 1193
Patent: ПРИМЕНЕНИЕ ЧАСТИЧЕК ТВЕРДОГО НОСИТЕЛЯ ДЛЯ УЛУЧШЕНИЯ ТЕХНОЛОГИЧЕСКИХ ХАРАКТЕРИСТИК ФАРМАЦЕВТИЧЕСКОГО АГЕНТА;ЗАСТОСУВАННЯ ЧАСТИНОК ТВЕРДОГО НОСІЯ ДЛЯ ПОЛІПШЕННЯ ТЕХНОЛОГІЧНИХ ХАРАКТЕРИСТИК ФАРМАЦЕВТИЧНОГО АГЕНТА (THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT)
Estimated Expiration: ⤷  Subscribe

Patent: 3224
Patent: ТАБЛЕТКИ ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ;ТАБЛЕТКИ ДЛЯ КОМБІНОВАНОЇ ТЕРАПІЇ (Normal;heading 1;heading 2;heading 3;TABLETS FOR COMBINATION THERAPY)
Estimated Expiration: ⤷  Subscribe

Uruguay

Patent: 424
Patent: COMPRIMIDOS CONTENIENDO ELIVITEGRAVIR PARA TRATAMIENTO DE INFECCIONES VIRALES
Estimated Expiration: ⤷  Subscribe

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SYMTUZA around the world.

Country Patent Number Title Estimated Expiration
Canada 2692331 MODULATEURS DES PROPRIETES PHARMACOCINETIQUES DE SUBSTANCES THERAPEUTIQUES (MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS) ⤷  Subscribe
South Korea 20150042869 치료제의 약동학 특성의 모듈레이터 (MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS) ⤷  Subscribe
Singapore 10201705929Q MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS ⤷  Subscribe
Taiwan 201268 ⤷  Subscribe
South Korea 20100040896 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for SYMTUZA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2487163 SPC/GB17/010 United Kingdom ⤷  Subscribe PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ATAZANAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR ATAZANAVIR SULFATE; REGISTERED: UK EU/1/15/1025/001 20150715; UK EU/1/15/1025/002 20150715
2487162 2016C/068 Belgium ⤷  Subscribe PRODUCT NAME: COBICISTAT ET DARUNAVIR; AUTHORISATION NUMBER AND DATE: EU/1/14/967 20141121
0513200 C00513200/01 Switzerland ⤷  Subscribe PRODUCT NAME: EMTRICITABINE; REGISTRATION NUMBER/DATE: SWISSMEDIC 56880 25.10.2004
1301519 300803 Netherlands ⤷  Subscribe PRODUCT NAME: TENOFOVIRALAFENAMIDE OF EEN ZOUT OF SOLVAAT DAARVAN, MET NAME TENOFOVIRALAFENAMIDEFUMARAAT; NATIONAL REGISTRATION NO/DATE: EU/1/15/1061/002 20151123; FIRST REGISTRATION: EU EU/1/15/1061/001 20151123
2487166 2016C/065 Belgium ⤷  Subscribe PRODUCT NAME: COBICISTAT AND TENOFOVIR ALAFENAMIDE; AUTHORISATION NUMBER AND DATE: EU/1/15/1061 20151123
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

SYMTUZA Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Symtuza

Introduction

Symtuza, a once-daily HIV medication developed by Johnson & Johnson's Janssen Pharmaceuticals, was approved by the FDA in 2018. This drug represents a significant addition to the treatment options for HIV, but it faces a highly competitive market. Here, we will delve into the market dynamics and the financial trajectory of Symtuza.

Market Approval and Indications

Symtuza is a combination of darunavir, a protease inhibitor, with cobicistat, emtricitabine, and tenofovir alafenamide. It is the first and only complete, darunavir-based single-tablet regimen for the treatment of HIV-1 in treatment-naive and certain virologically suppressed adults[1][4].

Competitive Landscape

The HIV treatment market is crowded and competitive, with several established players. At the time of Symtuza's approval, it had to contend with other recently approved drugs such as Gilead Sciences' Biktarvy and Juluca, developed by J&J and GlaxoSmithKline.

  • Biktarvy: This drug, approved early in 2018, combines the novel integrase inhibitor bictegravir with emtricitabine and tenofovir alafenamide. Biktarvy has been highly successful, with projected peak sales of $6 billion to $10 billion[1].
  • Juluca: Another competitor, Juluca is the first two-drug regimen for HIV, consisting of dolutegravir and rilpivirine. It offers a simpler treatment option, which can be a significant advantage in terms of adherence[1].

Clinical Trials and Efficacy

Symtuza's approval was based on two Phase 3 trials. The first trial showed that Symtuza was non-inferior to a combination of J&J's Prezista plus Gilead's Truvada in treatment-naive patients. The second trial found little difference in virologic failure or suppression rates between patients who stayed on Truvada plus a boosted protease inhibitor and those who switched to Symtuza[4].

Differentiation and Market Position

Given the competitive landscape, differentiating Symtuza is crucial. Here are a few key points:

  • Convenience: Symtuza offers the convenience of a single-tablet regimen, which can improve adherence.
  • Tolerability: The formulation is designed for improved tolerability, which can be a significant factor in patient compliance[1].
  • Black Box Warning: Symtuza carries a black box warning for post-treatment acute exacerbation of hepatitis B, a common caution with many HIV drugs[1][4].

Financial Performance

While Symtuza is an important addition to J&J's portfolio, its financial impact is relatively modest compared to other products.

  • Revenue Contribution: Symtuza does not contribute significantly to J&J's overall pharmaceutical revenue. For example, Edurant (rilpivirine), another HIV drug from J&J, generated $211 million in the second quarter of 2018, which is about 2% of J&J's pharmaceutical revenue[4].
  • Market Sales: The exact sales figures for Symtuza are not publicly disclosed in detail, but it is clear that it faces stiff competition from drugs like Biktarvy, which has seen substantial sales growth. Biktarvy's sales were projected at $1 billion in its first year and are expected to peak at $6 billion to $10 billion[1].

Impact on J&J's Financials

J&J's overall financial performance is diverse and not heavily reliant on HIV drugs.

  • Q4 and Full-Year Results: In 2023, J&J reported a 7.3% increase in fourth-quarter sales and a 10.6% increase in full-year sales, driven by various segments including Innovative Medicine and MedTech. However, the specific contribution of Symtuza to these figures is not highlighted[2].

Market Trends and Future Outlook

The HIV treatment market continues to evolve with new drugs and treatment regimens.

  • Patient Uptake: The continued patient uptake of newer drugs like Biktarvy and Descovy has been a trend. Symtuza needs to capture a significant share of this market to be financially viable[3].
  • Competition and Innovation: The market is driven by innovation, with companies continuously developing new and improved treatments. Symtuza's success will depend on its ability to differentiate itself and adapt to these market dynamics.

Key Takeaways

  • Competitive Market: Symtuza enters a crowded market with established competitors like Biktarvy and Juluca.
  • Differentiation: Its single-tablet regimen and improved tolerability are key differentiators.
  • Financial Impact: Symtuza's financial contribution to J&J is relatively modest.
  • Market Trends: The market is driven by patient uptake of newer, more convenient treatments.

FAQs

Q: What is Symtuza, and how is it used? A: Symtuza is a once-daily HIV medication that combines darunavir, cobicistat, emtricitabine, and tenofovir alafenamide. It is used for the treatment of HIV-1 in treatment-naive and certain virologically suppressed adults.

Q: What are the main competitors of Symtuza in the HIV treatment market? A: The main competitors include Gilead Sciences' Biktarvy and Juluca, developed by J&J and GlaxoSmithKline.

Q: What are the key differentiators of Symtuza? A: Symtuza offers the convenience of a single-tablet regimen and is designed for improved tolerability.

Q: Does Symtuza carry any significant warnings? A: Yes, Symtuza carries a black box warning for post-treatment acute exacerbation of hepatitis B.

Q: How significant is Symtuza's contribution to J&J's overall revenue? A: Symtuza's contribution to J&J's revenue is relatively modest compared to other pharmaceutical products.

Sources

  1. FiercePharma: Janssen wins FDA nod for Symtuza but the once-daily HIV drug ...
  2. Johnson & Johnson Investor Relations: Johnson & Johnson Reports Q4 and Full-Year 2023 Results
  3. Gilead Sciences News: Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results
  4. BioPharma Dive: Where does J&J's new drug fit in the crowded HIV market?

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.